Lexeo Therapeutics (LXEO) Competitors

Terns Pharmaceuticals (NASDAQ:TERN) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Which has better earnings & valuation, TERN or LXEO?

Terns Pharmaceuticals has higher earnings, but lower revenue than Lexeo Therapeutics. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Terns Pharmaceuticals	N/A	N/A	-$88.85M	-$1.04	-6.66
Lexeo Therapeutics	$650K	407.08	-$98.33M	-$3.26	-1.50

Is TERN or LXEO more profitable?

Terns Pharmaceuticals' return on equity of -27.35% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Terns Pharmaceuticals	N/A	-27.35%	-26.18%
Lexeo Therapeutics	N/A	-94.65%	-73.36%

Do institutionals and insiders hold more shares of TERN or LXEO?

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer TERN or LXEO?

Terns Pharmaceuticals presently has a consensus target price of $15.63, suggesting a potential upside of 125.47%. Lexeo Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 212.93%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Terns Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Terns Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Lexeo Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to TERN or LXEO?

In the previous week, Lexeo Therapeutics had 10 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 12 mentions for Lexeo Therapeutics and 2 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.42 beat Lexeo Therapeutics' score of -0.14 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Terns Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, TERN or LXEO?

Terns Pharmaceuticals has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.

Summary

Lexeo Therapeutics beats Terns Pharmaceuticals on 8 of the 14 factors compared between the two stocks.